EP1606301A4 - Aptamer therapeutics useful in ocular pharmacotherapy - Google Patents
Aptamer therapeutics useful in ocular pharmacotherapyInfo
- Publication number
- EP1606301A4 EP1606301A4 EP04704120A EP04704120A EP1606301A4 EP 1606301 A4 EP1606301 A4 EP 1606301A4 EP 04704120 A EP04704120 A EP 04704120A EP 04704120 A EP04704120 A EP 04704120A EP 1606301 A4 EP1606301 A4 EP 1606301A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmacotherapy
- ocular
- therapeutics useful
- aptamer therapeutics
- aptamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44134703P | 2003-01-21 | 2003-01-21 | |
US441347P | 2003-01-21 | ||
US46309503P | 2003-04-15 | 2003-04-15 | |
US463095P | 2003-04-15 | ||
US46417903P | 2003-04-21 | 2003-04-21 | |
US464179P | 2003-04-21 | ||
US46505503P | 2003-04-23 | 2003-04-23 | |
US465055P | 2003-04-23 | ||
US46962803P | 2003-05-08 | 2003-05-08 | |
US469628P | 2003-05-08 | ||
US47468003P | 2003-05-29 | 2003-05-29 | |
US474680P | 2003-05-29 | ||
US49101903P | 2003-07-29 | 2003-07-29 | |
US491019P | 2003-07-29 | ||
US51207103P | 2003-10-17 | 2003-10-17 | |
US512071P | 2003-10-17 | ||
US53720104P | 2004-01-16 | 2004-01-16 | |
US53704504P | 2004-01-16 | 2004-01-16 | |
US537201P | 2004-01-16 | ||
US537045P | 2004-01-16 | ||
PCT/US2004/001661 WO2004064760A2 (en) | 2003-01-21 | 2004-01-21 | Aptamer therapeutics useful in ocular pharmacotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1606301A2 EP1606301A2 (en) | 2005-12-21 |
EP1606301A4 true EP1606301A4 (en) | 2006-06-14 |
Family
ID=32777434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04704120A Withdrawn EP1606301A4 (en) | 2003-01-21 | 2004-01-21 | Aptamer therapeutics useful in ocular pharmacotherapy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1606301A4 (en) |
JP (1) | JP2006516288A (en) |
AU (1) | AU2004206955A1 (en) |
CA (1) | CA2513004A1 (en) |
WO (1) | WO2004064760A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
BRPI0509911A (en) * | 2004-04-13 | 2007-09-18 | Osi Eyetech Inc | method for inhibiting the activity of a separate site of an aptamer binding site in a ligand, methods of increasing the antagonist, receptor, ligand-binding aptamer, antagonist, ligand of a receptor-binding aptamer a vegf aptamer, and a vegfr aptamer ligand, method to increase an antagonist property of an aptamer that targets a protein that interacts with a second protein, method to identify an aptamer conjugate, methods to release a biologically molecule active, nucleic acid, an aptamer, and an anti-vegf aptamer to an eye, compound, composition to release a biologically active molecule to an eye |
EP3034089A1 (en) * | 2004-11-02 | 2016-06-22 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
WO2006119643A1 (en) * | 2005-05-12 | 2006-11-16 | Replicor Inc. | Anti-ocular angiogenesis molecules and their uses |
EP4159220A1 (en) * | 2006-03-08 | 2023-04-05 | Archemix LLC | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
CA3027780A1 (en) | 2008-09-22 | 2010-03-25 | Phio Pharmaceuticals Corp. | Reduced size self-delivering rnai compounds |
JP2010100615A (en) * | 2008-09-25 | 2010-05-06 | Santen Pharmaceut Co Ltd | Prophylactic or curative agent for retinal disease including polyalkylene glycol as active ingredient |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US8993715B2 (en) * | 2009-07-06 | 2015-03-31 | Canon Kabushiki Kaisha | Labeled protein and method for obtaining the same |
JP6041373B2 (en) * | 2010-02-01 | 2016-12-07 | Necソリューションイノベータ株式会社 | Aptamer molecule that binds to TNF-α |
WO2011119871A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
ES2742284T3 (en) | 2012-03-28 | 2020-02-13 | Somalogic Inc | Aptamers against PDGF and VEGF and their use in the treatment of conditions mediated by PDGF and VEGF |
BR112016000546A2 (en) * | 2013-07-12 | 2017-11-21 | Ophthotech Corp | methods to treat or prevent eye conditions |
EP3693472A1 (en) | 2013-09-09 | 2020-08-12 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
CA2932753A1 (en) * | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
US11013756B2 (en) | 2015-12-04 | 2021-05-25 | Zenyaku Kogyo Co., Ltd. | Anti-IL-17 aptamer having improved retention in blood |
CA3012718A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
WO2018148333A1 (en) * | 2017-02-08 | 2018-08-16 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
TW202436291A (en) | 2018-01-19 | 2024-09-16 | 美商胞質動力學公司 | Cardiac sarcomere inhibitors |
US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
WO2020120256A1 (en) * | 2018-12-11 | 2020-06-18 | Université De Strasbourg | Aptamer and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001009156A1 (en) * | 1999-07-29 | 2001-02-08 | Gilead Sciences, Inc. | HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6458559B1 (en) * | 1998-04-22 | 2002-10-01 | Cornell Research Foundation, Inc. | Multivalent RNA aptamers and their expression in multicellular organisms |
CA2714081C (en) * | 2000-02-10 | 2013-08-06 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
-
2004
- 2004-01-21 JP JP2006501092A patent/JP2006516288A/en active Pending
- 2004-01-21 WO PCT/US2004/001661 patent/WO2004064760A2/en active Search and Examination
- 2004-01-21 AU AU2004206955A patent/AU2004206955A1/en not_active Abandoned
- 2004-01-21 CA CA002513004A patent/CA2513004A1/en not_active Abandoned
- 2004-01-21 EP EP04704120A patent/EP1606301A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001009156A1 (en) * | 1999-07-29 | 2001-02-08 | Gilead Sciences, Inc. | HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
Also Published As
Publication number | Publication date |
---|---|
EP1606301A2 (en) | 2005-12-21 |
JP2006516288A (en) | 2006-06-29 |
WO2004064760A2 (en) | 2004-08-05 |
WO2004064760A3 (en) | 2005-10-27 |
AU2004206955A1 (en) | 2004-08-05 |
CA2513004A1 (en) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1606301A4 (en) | Aptamer therapeutics useful in ocular pharmacotherapy | |
GB0308841D0 (en) | Improvements in convenience rolls | |
GB0307802D0 (en) | Selecting functions in context | |
GB0317615D0 (en) | Improvements in or relating to stairlifts | |
GB2401029B (en) | Improvements in furniture | |
GB0317618D0 (en) | Improvements in or relating to stairlifts | |
IL165219A0 (en) | Moisture-management in hydrophilic fibers | |
GB0306367D0 (en) | Improvements in or relating to stairlifts | |
GB0328314D0 (en) | Therapeutics | |
GB2423462B (en) | Improvements in garments | |
GB2401161B (en) | Improvements in movement controls | |
GB0428089D0 (en) | Improvements in automotive technology | |
GB0328262D0 (en) | Improvements in movement controls | |
GB2417734B (en) | Improvements in worktops | |
GB0418260D0 (en) | Improvements in mirrors | |
GB0324811D0 (en) | Improvements in magnetopolariscopes | |
GB0421536D0 (en) | Improvements in or relating to eyewear | |
GB0412558D0 (en) | Improvements in vehicle progress indication | |
GB0419498D0 (en) | Improvements in worktops | |
GB0512768D0 (en) | Recreational article | |
IL163758A0 (en) | Improvments in showers | |
GB0423631D0 (en) | Improvements in autostereoscopic design | |
AU2004902291A0 (en) | Improvements in clothing | |
GB0423629D0 (en) | Improvements in autostereoscopic displays | |
GB0423607D0 (en) | Improvements in autostereoscopic displays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050818 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101AFI20060215BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060515 |
|
17Q | First examination report despatched |
Effective date: 20070627 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080108 |